AIM
AKCA

Aigen Investment Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Aigen Investment Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,676
Closed -$256K – 1201
2020
Q2 		$256K Buy
18,676
+4,161
+29% +$64.2K 0.03% 646
2020
Q1 		$208K Buy
+14,515
New +$238K 0.03% 695

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aigen Investment Management's AKCA Position: Q3 2020 in Review

Aigen Investment Management sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 18,676 shares — an estimated $256K sold.

Aigen Investment Management first reported a position in AKCA in Q1 2020 and held it in 2 quarters. The position peaked at $256K in Q2 2020. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Aigen Investment Management reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Aigen Investment Management sold 18,676 Akcea Therapeutics Inc shares in Q3 2020, an estimated $256K.
  • Aigen Investment Management first reported a position in Akcea Therapeutics Inc in Q1 2020 and held it in 2 quarters.
  • Aigen Investment Management's Akcea Therapeutics Inc position peaked at $256K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Aigen Investment Management's 13F filing for Q3 2020, filed 6 Nov 2020.